Tuberculosis treatment outcome in a tertiary care setting

Annals of Saudi Medicine

Volumn 27, Issue 3, 2007, Pages 171-174

  Bukhary, Zakeya A ^a   Alrajhi, Abdulrahman A ^b  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COMORBIDITY; EARLY DIAGNOSIS; EXTRAPULMONARY TUBERCULOSIS; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; SAUDI ARABIA; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34447343573     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2007.171     Document Type: Article

References (19)

1. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005;7:5-14
2. Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr opin Pulm Med 2005;11:189-194
3. World Health Organization. Tuberculosis global and regional incidence. Geneva, Switzerland: WHO, 2004:Fact Sheet 104.
4. Borgdorff MW, Floyd K and Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ 2002;80:217-227.
5. Pablos-Mendez A, Sterling TR and Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis, JAMA 1996;276:1223-1228.
6. Groth-Petersen B. The significance of chemotherapy for relapses from respiratory tuberculosis. Scand J Respir Dis 1976;57:108-112.
7. Noertjojo K, Tam CM, Chan SL and Chan-Yeung MM. Extra-pulmonary and pulmonary tuberculosis in Hong Kong. Int J Tuberc Lung Dis 2002;6:879-886.
8. Wobeser W, Yuan L and Naus M. Outcome of pulmonary tuberculosis treatment in the tertiary care setting--Toronto 1992/93. Tuberculosis Treatment Completion Study Group. CMAJ 1999;160:789-794.
9. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva, 1994
10. Samman Y, Krayem A, Haidar M, et al. Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance. Clin Microbiol Infect 2003;9:289-294.
11. Kobashi Y, Matsushima T. Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy. Intern Med 2002;41:1103-1110.
12. Froude JR, Kingston M. Extrapulmonary tuberculosis in Saudi Arabia, a review of 162 cases. King Faisal Specialist Hospital Medical Journal 1982;2:85-95.
13. Alrajhi AA, Abdulwahab S, Almodovar E and Al-Abdely HM. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J 2002;23:305-310.
14. Bukhary ZA, Alrajhi AA. Extrapulmonary tuberculosis, clinical presentation and outcome. Saudi Med J 2004;25:881-885.
15. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW and Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002;6:1114-1117.
16. Lawn SO, Acheampong JW. Pulmonary tuberculosis in adults: factors associated with mortality at a Ghanaian teaching hospital. West Afr J Med 1999;18:270-274.
17. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcome in Europe: a systemic review. Eur Respir J 2005;26(3):503-510
18. Ormerod LP, Horsfield N and Green RM. Tuberculosis treatment outcome monitoring: Blackburn 1988-2000. Int J Tuberc Lung Dis 2002;6:662-665.
19. Sevim T, Atac G, Gungor G, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2002;6:320-325.